Biosergen AB (FRA:8N1) Buildings And Improvements : €0.00 Mil (As of Mar. 2025)

View and export this data going back to 2021. Start your Free Trial

What is Biosergen AB Buildings And Improvements?

Biosergen AB Buildings And Improvements Historical Data

The historical data trend for Biosergen AB's Buildings And Improvements can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biosergen AB Buildings And Improvements Chart

Biosergen AB Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Dec24

Buildings And Improvements

Biosergen AB Quarterly Data
	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Buildings And Improvements	Get a 7-Day Free Trial													-	-	-	-	-

Biosergen AB Buildings And Improvements Calculation

Buildings are typically valued at the time of acquisition or construction. Broker and architect fees, permits, etc. can be covered within this category. Building components, such as a roof, are normally recorded separately in an asset register since the value and useful lives of these components equal much less than the building itself.

Building improvements that extend the useful life of a building will fall into the category of “building improvements” and should be capitalized. Improvements are commonly recorded at acquisition cost. Building improvement examples include roofing, remodeling, replacements, etc.

Biosergen AB Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Biosergen AB (FRA:8N1) » Definitions » Buildings And Improvements

Comparable Companies

Traded in Other Exchanges

BIOSGN:Sweden

Address

Fogdevreten 2, Solna, SWE, 17165

Website

https://www.biosergen.net

Biosergen AB is a clinical stage biotechnology company advancing the treatment of life-threatening fungal infections. Biosergen' s mission is to develop the drug candidate BSG005 into a superior antifungal therapy with broader efficacy and improved safety over existing treatments. BSG005 potential is to eliminate fungal infections rather than just slowing their growth, reducing the risk of resistance.

Biosergen AB Headlines

No Headlines